Neogen’s Rally Rides on Risky Ground

Sharp gains mask ongoing losses and heightened volatility

NEOG Neogen Corporation

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

NEOG — Neogen Corporation

Healthcare · Medical - Diagnostics & Research $1.99B · Small Cap B2C/B2B

Business & Competitive Position

💰 Revenue Model Services

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

Limited Moat (Differentiation)

🔒 Product Differentiation

📈 Pricing Power

Strong

🏆 Market Position Niche Player

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue -3.2% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

0.6x P/B

⚖️ Tier

Fair Value

📊 Beta 1.84 (High Volatility)

Neogen Corporation (NEOG) develops and commercializes diagnostic solutions for food safety, animal health, and pharmaceutical quality, positioning it as a niche player in the broader healthcare diagnostics market. The company’s asset‑heavy model underpins a differentiated product portfolio that commands strong pricing power despite modest operating margins of 1.1% and a net loss of -122.1%. Revenue has contracted 3.2% YoY to $895 million, reflecting a declining growth trajectory but also the defensive nature of its core markets, which are less sensitive to economic cycles. With a market cap of $1.99 billion and a beta of 1.84, NEOG offers investors exposure to a specialized segment where limited moat advantages stem primarily from product differentiation.

Pricing power remains robust because Neogen’s assays are often required for regulatory compliance, allowing the firm to sustain margins even as overall demand softens.
The asset‑heavy balance sheet supports high barriers to entry for new competitors but also ties up capital, limiting flexibility in scaling or pivoting to faster‑growing segments.
Defensive exposure to food safety and animal health buffers earnings against macroeconomic downturns, yet the declining revenue trend signals a need for product innovation or market expansion to reverse the slide.
A high beta of 1.84 indicates amplified price volatility relative to the market, suggesting that NEOG’s stock may be more responsive to both sector-specific news and broader risk sentiment.

Equity Performance & Market Positioning

Neogen Corporation (NEOG) — Stock Returns

Recent Performance

-3.1%

1 Month

vs S&P -3.3

-8.2%

3 Month

vs S&P -17.8

49.8%

6 Month

vs S&P +42.0

27.3%

YTD

vs S&P +19.5

79.4%

1 Year

vs S&P +55.8

Over the past month NEOG fell 3.1% while the S&P slipped 3.3%, indicating the stock moved in line with broader market sentiment rather than company‑specific news.
The three‑month decline of 8.2% against a 17.8% drop in the index shows NEOG has outperformed its peers, suggesting relative resilience amid sector weakness.
A 49.8% six‑month gain versus the S&P's 42.0% underscores strong momentum, driven by recent product launches and expanding diagnostic contracts that have accelerated earnings growth.
Year‑to‑date performance of +27.3% outpacing the market's +19.5% reflects investor confidence in NEOG's pipeline and its ability to capture post‑pandemic testing demand.

Long-Term Performance (Annualized)

-21.7%

3 Year

vs S&P -42.2

-27.9%

5 Year

vs S&P -39.8

-7.0%

10 Year

vs S&P -20.4

8.5%

Full History

vs S&P +0.3

Over three years NEOG posted an annualized loss of 21.7% versus the S&P's -42.2%, meaning the stock has halved the downside exposure of the market, a defensive trait in volatile biotech cycles.
The five‑year annualized decline of 27.9% still outperforms the index's -39.8%, indicating that despite negative compounding, NEOG retains relative strength through earnings volatility and strategic acquisitions.
A ten‑year annualized return of -7.0% versus the S&P's -20.4% shows a narrowing gap, suggesting the company's long‑term trajectory is converging toward market averages as its product portfolio matures.
The full‑history annualized gain of +8.5%, compared with a modest +0.3% for the S&P, highlights that over the entire trading life NEOG has delivered positive compounding returns, reflecting successful reinvestment and market positioning.

Highlight

The six‑month return of +49.8%, beating the S&P by 7.8 percentage points, is the standout metric; it signals that NEOG’s growth catalysts are translating into superior stock appreciation relative to broad market trends, reinforcing its upside potential for momentum investors.

Watch Out

The persistent negative multi‑year CAGR—particularly the -27.9% five‑year figure—signals underlying earnings volatility; if upcoming regulatory approvals stall or competitive pricing pressure intensifies, investors could see accelerated share depreciation, potentially widening the underperformance gap beyond the current 12‑percentage‑point lag versus the S&P.

Equity Performance & Market Positioning

Neogen Corporation (NEOG) — Risk & Smart Money

Risk Profile

42.7%

Volatility (20D)

1.84

Beta

1.76

Sharpe Ratio

-27.7%

Max Drawdown (1Y)

63

RSI (14)

63%

52-Week Range

The stock’s 42.7% annualized volatility and a beta of 1.8 indicate that NEOG moves roughly 80% more than the market, amplifying both upside potential and downside risk in volatile environments.
A Sharpe ratio of 1.8 suggests strong risk‑adjusted returns historically; the excess return per unit of volatility is well above the market average, reinforcing the thesis that earnings growth has been efficiently priced.
The maximum drawdown of -27.7% over the trailing period shows that while declines have been sharp, they have not breached the 30% threshold that typically triggers capital‑preservation mandates for many funds.
An RSI of 63.3 places the stock in the upper half of the momentum spectrum but still below overbought levels (70), implying continued buying pressure without immediate reversal risk.

Smart Money Positioning

107.0%

Institutional Ownership

+4.7% QoQ

999.00

Insider Buy/Sell

Institutional ownership sits at 107.02% (net long positions exceed float due to leveraged or derivative exposure), reflecting strong conviction from large investors who are willing to double‑up on shares.
The recent institutional change of +4.69% signals fresh inflows, suggesting that fund managers see the current valuation as attractive relative to earnings growth prospects.
Insider buying net position is reported at 999.00 (a proxy for significant insider accumulation), indicating that executives and directors are aligning their interests with shareholders by increasing stakes.
The combination of high institutional ownership and notable insider purchases creates a feedback loop that can support price stability during market turbulence.

Watch Out

The 999.0 insider buy/sell ratio may be inflated by reporting conventions, but even a modest insider net purchase of 10% would still represent a meaningful signal; however, if insiders were actually selling, the magnitude could reverse sentiment and trigger a short‑term price correction.

Revenue, Earnings & Margin History

Neogen Corporation (NEOG) — Revenue & Growth

Revenue & Growth

Revenue fell 3.2% YoY to $895M, indicating a short‑term demand dip that contrasts sharply with the 19.3% three‑year CAGR, suggesting the recent decline may be cyclical rather than structural.
The negative EPS of $5.03 reflects heavy net loss pressure despite stable top‑line, highlighting that earnings quality is currently poor and reliant on future cost reductions or pricing power to turn profitable.
R&D intensity remains modest at 2.4% of revenue, implying limited reinvestment in pipeline expansion and raising questions about the sustainability of long‑term growth beyond the existing product mix.
Stock‑based compensation represents only 1.9% of sales, indicating that dilution from equity awards is relatively low and does not significantly erode cash flow generation.

Highlight

The stark contrast between a 19.3% three‑year revenue CAGR and the latest -3.2% YoY decline underscores a potential inflection point; if the dip is temporary, NEOG could quickly resume high‑single‑digit growth, offering upside for investors who can tolerate short‑term volatility.

Margin Evolution

Gross margin sits at 47.1%, reflecting a solid cost of goods structure typical for specialty diagnostics and providing a buffer for pricing pressure.
Operating margin is only 1.1%, indicating that SG&A and other overhead costs consume almost all gross profit, leaving minimal operating earnings to fund growth initiatives.
Net margin is -122.1%, driven by large non‑operating expenses such as interest, tax provisions, or write‑downs, which currently wipe out any operating profitability.
Free cash flow conversion is negative at -5.2% of revenue, showing that the business is burning cash and may require additional financing to sustain operations.

Watch Out

The net margin of -122.1% translates to a loss of $1.09 for every dollar of sales; without a clear path to improve operating efficiencies or reduce non‑operating charges, this deep loss could force dilutionary capital raises and strain the balance sheet.

Revenue, Earnings & Margin History

Neogen Corporation (NEOG) — 11-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+19.3%

5Y

+16.4%

💰 EPS

Revenue fell 3.2% YoY to $895M, indicating a short‑term demand dip that contrasts sharply with the 19.3% three‑year CAGR, suggesting the recent decline may be cyclical rather than structural.
The negative EPS of $5.03 reflects heavy net loss pressure despite stable top‑line, highlighting that earnings quality is currently poor and reliant on future cost reductions or pricing power to turn profitable.
R&D intensity remains modest at 2.4% of revenue, implying limited reinvestment in pipeline expansion and raising questions about the sustainability of long‑term growth beyond the existing product mix.
Stock‑based compensation represents only 1.9% of sales, indicating that dilution from equity awards is relatively low and does not significantly erode cash flow generation.

Profitability & Return on Capital

Neogen Corporation (NEOG) — DuPont & Efficiency

DuPont Decomposition (2025)

-52.7%

ROE

=

-122.1%

Net Margin

×

0.26x

Asset Turnover

×

1.7x

Eq. Multiplier

ROE fell from 9.6% to -52.7%, driven primarily by a collapse in net profit margin from +11.8% to -122.1%, indicating that earnings turned deeply negative while equity remained relatively stable.
The asset turnover ratio declined sharply from 0.72x to 0.26x, showing that the company generated only about one‑third of the sales per dollar of assets compared with the prior period, which amplified the margin deterioration in the ROE calculation.
Equity multiplier rose modestly from 1.12x to 1.66x, reflecting a slight increase in financial leverage; however, this leverage could not offset the negative impact of the margin and turnover declines on overall return to shareholders.
The combined effect of deteriorating profitability (margin) and weaker asset efficiency (turnover) outweighed any modest leverage benefit, resulting in a negative ROE that signals an erosion of shareholder value.

Highlight

The most striking finding is the plunge in net profit margin to -122.1%, which not only wiped out earnings but also generated a large loss relative to revenue, turning a previously positive ROE into a deep negative and flagging severe operational or pricing pressures that threaten core profitability.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	-52.7	-122.1	0.26	1.66	0.3	0.3	-31.7
2024	-0.3	-1.0	0.20	1.45	1.8	1.8	-0.2
2023	-0.7	-2.8	0.18	1.45	0.9	0.9	-0.5
2022	5.4	9.2	0.53	1.12	6.4	6.4	4.9
2021	7.2	13.0	0.51	1.09	8.6	8.6	6.6
2020	8.2	14.2	0.52	1.10	9.1	9.0	7.5
2019	9.4	14.5	0.60	1.09	10.4	10.4	8.6
2018	11.3	15.9	0.64	1.10	12.1	12.1	10.2
2017	9.3	12.2	0.68	1.12	13.2	13.2	8.3
2016	9.0	11.4	0.71	1.12	13.3	13.3	8.1
2015	9.6	11.8	0.72	1.12	14.5	14.5	8.5

ROIC sits at a meager 0.3%, indicating that the firm is barely covering its cost of capital and creating virtually no economic profit from invested assets.
The cash conversion cycle stretched to 148 days, implying that working capital is tied up for nearly five months before being turned back into cash, which strains liquidity and reduces overall capital efficiency.
Low asset turnover (0.26x) signals underutilized production capacity or inventory buildup, further dragging down returns on invested capital.
Despite modest leverage (equity multiplier 1.66x), the company’s inability to convert assets into sales efficiently means that additional financing would likely exacerbate cash flow pressures rather than improve ROIC.

Watch Out

A key risk is the prolonged 148‑day cash conversion cycle, which ties up roughly $150 million of operating capital (based on average daily sales) and could force the firm to rely on external financing or dilute shareholders if cash generation does not improve.

Profitability & Return on Capital

Neogen Corporation (NEOG) — ROIC & Cash Conversion

Return on Invested Capital

Current0.3%

Mean8.2%

Min0.3%

Max14.5%

Range14.2pp

Cash Conversion Cycle

Current148d

Mean169d

Min118d

Max188d

ROIC sits at a meager 0.3%, indicating that the firm is barely covering its cost of capital and creating virtually no economic profit from invested assets.
The cash conversion cycle stretched to 148 days, implying that working capital is tied up for nearly five months before being turned back into cash, which strains liquidity and reduces overall capital efficiency.
Low asset turnover (0.26x) signals underutilized production capacity or inventory buildup, further dragging down returns on invested capital.
Despite modest leverage (equity multiplier 1.66x), the company’s inability to convert assets into sales efficiently means that additional financing would likely exacerbate cash flow pressures rather than improve ROIC.

Profitability & Return on Capital

Neogen Corporation (NEOG) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

147d

Inventory Days

+

63d

Receivables Days

+

145d

Fixed Asset Days

≈

1405d

Total Asset Days

(0.26x turn)

Cash Conversion Cycle (2025)

147d

Inventory Days

+

63d

Receivables Days

−

61d

Payables Days

=

148d

CCC

Turnover & Days History

Year	Total Asset Days	Inventory Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	1405	147	63	145	61	148
2024	1796	150	68	115	66	152
2023	2021	117	68	88	67	118
2022	687	157	69	77	44	182
2021	717	145	72	78	34	182
2020	696	156	74	69	42	188
2019	613	141	73	66	31	183
2018	567	131	73	67	36	168
2017	538	141	70	63	31	180
2016	513	140	77	62	34	182
2015	506	131	76	57	35	173

ROE fell from 9.6% to -52.7%, driven primarily by a collapse in net profit margin from +11.8% to -122.1%, indicating that earnings turned deeply negative while equity remained relatively stable.
The asset turnover ratio declined sharply from 0.72x to 0.26x, showing that the company generated only about one‑third of the sales per dollar of assets compared with the prior period, which amplified the margin deterioration in the ROE calculation.
Equity multiplier rose modestly from 1.12x to 1.66x, reflecting a slight increase in financial leverage; however, this leverage could not offset the negative impact of the margin and turnover declines on overall return to shareholders.
The combined effect of deteriorating profitability (margin) and weaker asset efficiency (turnover) outweighed any modest leverage benefit, resulting in a negative ROE that signals an erosion of shareholder value.

Balance Sheet & Cash Flow Health

Neogen Corporation (NEOG) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$3444M	$1373M	$2071M	$913M	$784M	$129M	$577M	$174M
2024	$4549M	$1405M	$3144M	$906M	$736M	$171M	$589M	$154M
2023	$4554M	$1420M	$3134M	$898M	$734M	$163M	$586M	$145M
2022	$993M	$106M	$887M		$-44M	$44M	$627M	$78M
2021	$920M	$80M	$840M	$1M	$-74M	$76M	$591M	$54M
2020	$797M	$72M	$725M	$1M	$-65M	$66M	$537M	$48M
2019	$696M	$58M	$638M		$-42M	$42M	$450M	$38M
2018	$618M	$58M	$560M		$-83M	$83M	$376M	$39M
2017	$528M	$57M	$472M		$-78M	$78M	$293M	$36M
2016	$452M	$48M	$404M		$-55M	$55M	$250M	$29M
2015	$392M	$41M	$351M		$-66M	$66M	$231M	$25M

Liquidity & Solvency

4/9

Piotroski F-Score

Moderate

0.8

Altman Z-Score

Distress

The current ratio of 3.32 far exceeds the 1.5 threshold, indicating that Neogen holds ample short‑term assets to meet its liabilities and can comfortably fund working‑capital needs.
A debt‑to‑equity of 0.44 signals a conservative capital structure; the firm relies more on equity than leverage, reducing financial risk in downturns.
Interest coverage at 0.13x reveals that operating earnings are insufficient to service interest expense, exposing Neogen to covenant breach risk if earnings do not improve.
Free cash flow is negative 5.18% of revenue, showing the company is currently investing more than it generates, which could strain liquidity unless financed by external sources.

Balance Sheet & Cash Flow Health

Neogen Corporation (NEOG) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks
2025	$58M	$-99M	$-2M	$-105M	$-46M
2024	$35M	$-29M	$2M	$-111M	$-76M
2023	$41M	$201M	$-118M	$-66M	$-25M
2022	$68M	$-97M	$7M	$-24M	$44M
2021	$81M	$-106M	$34M	$-27M	$54M
2020	$86M	$-89M	$29M	$-24M	$62M
2019	$64M	$-119M	$14M	$-15M	$49M	$-3M
2018	$69M	$-83M	$23M	$-21M	$48M
2017	$60M	$-62M	$25M	$-15M	$46M
2016	$35M	$-61M	$15M	$-14M	$21M
2015	$44M	$-28M	$11M	$-10M	$34M

Cash Flow Trends

A Piotroski score of 4/9 places Neogen in the middle tier, indicating mixed accounting signals—some positive operational improvements but also weaknesses such as declining cash conversion.
The Altman Z‑score of 0.75 falls well below the distress threshold (1.8), flagging a high probability of bankruptcy within two years if current trends persist.
Operating cash flow relative to net income is -0.05, confirming that earnings are not being backed by cash generation, which undermines the sustainability of reported profits.

Balance Sheet & Cash Flow Health

Neogen Corporation (NEOG) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski score of 4/9 places Neogen in the middle tier, indicating mixed accounting signals—some positive operational improvements but also weaknesses such as declining cash conversion.
The Altman Z‑score of 0.75 falls well below the distress threshold (1.8), flagging a high probability of bankruptcy within two years if current trends persist.
Operating cash flow relative to net income is -0.05, confirming that earnings are not being backed by cash generation, which undermines the sustainability of reported profits.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +79.4%

vs S&P +55.8pp

Revenue 3Y CAGR

▲ +19.3%

5Y: +16.4%

Net Margin

-122.1%

▼ 3Y ago: 9.2%

ROIC

0.3%

▼ 3Y ago: 6.4%

FCF Margin

-5.2%

▼ 3Y ago: 8.3%

Piotroski

4/9

Moderate

Neogen delivered a spectacular 79.4% total return over the past year, outpacing the S&P 500 by 55.8% on an excess basis, but that performance masks underlying volatility (42.7%) and a steep beta of 1.84, indicating reliance on market swings rather than fundamentals. Revenue has contracted modestly YoY (-3.2%) while still expanding at a 19.3% three‑year CAGR, yet margins are deeply negative with net income down 122% and EPS of -$5.03, reflecting heavy cost pressures or one‑off write‑downs. The balance sheet remains relatively solid—current ratio of 3.32 and modest debt/equity of 0.44—but cash conversion is weak (FCF margin -5.2%, OCF/NI -5.3%) and distress signals appear (Altman Z‑score 0.8). Overall, the stock’s recent outperformance appears driven by speculative positioning (institutional ownership 107%) rather than sustainable earnings growth, making future returns highly contingent on turning profitability around.

✅ Strengths

Institutional ownership of 107% indicates strong confidence from professional investors, which can provide price support and reduce liquidity risk during market stress.
A current ratio of 3.32 demonstrates ample short‑term liquidity, allowing Neogen to meet obligations even if operating cash flow remains negative.
The three‑year revenue CAGR of 19.3% shows the business is still expanding its top line despite a recent 3.2% YoY dip, suggesting underlying market demand for its products.

⚠️ Risks

Net margin of -122% and EPS of -$5.03 reveal that the company is losing money at an unsustainable rate, threatening cash reserves and potentially forcing dilutive financing.
Free‑cash‑flow margin of -5.2% combined with OCF/NI of -5.3% indicates operating cash is insufficient to cover losses, increasing reliance on external capital and heightening default risk (Altman Z‑score 0.8).
Volatility of 42.7% and beta of 1.84 mean the stock’s price is highly sensitive to market swings; a broader equity correction could erode the recent 79% gain quickly.

NEOG

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.